Pharmabiz16d
Novartis ribociclib recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Guidelines
This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...
The Motley Fool19d
What Is the Fortune 500?
Fortune 500 ranks top 500 U.S. companies by revenue, spotlighting reliable investment targets. Fortune Global 500 lists top 500 global firms, helping diversify investment portfolios. To join ...
Novartis24d
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...
Reuters27d
S&P 500 ends at fresh record high, as Dow scales 43k for first time
With 41 S&P 500 companies expected to report results this week, this flood of new data points from corporate America will help investors assess the health of the U.S. economy, and whether ...
The Week27d
FDA Approves IMULDOSA® ustekinumab-srlf Accord BioPharma's Biosimilar to STELARA® ustekinumab for the Treatment of Chronic Inflammatory Conditions
With the approval of IMULDOSA, Accord BioPharma's (A division of Intas Pharmaceuticals) biosimilar portfolio continues to grow while expanding treatment options appropriate for patients AHMEDABAD, ...